Abstract

BackgroundTuberculosis (TB) is one of the most prevalent cause of death due to a single pathogen. Bacillus Calmette Guérin (BCG) is the only vaccine available for clinical use that protects against miliary TB; however, this vaccine has shown variable levels of efficacy against pulmonary TB. In India, a single dose of BCG vaccine is given and there are few countries where repeated doses of BCG are given. The incidence of TB in India is very high inspite of primary vaccination in neonatal period and therefore requires consideration for repeated immunization.MethodsTo improve BCG immunogenicity, we have evaluated specific antimycobacterial immune responses (anti-BCG IgG and IFN-γ), T cell activity-ADA, CD4 and CD8 T cell count, and CD4/CD8 ratio in a peripheral blood mononuclear cells (PBMC) model using boost immunization protocols with the BCG vaccine. PBMC were induced with a repeat dose of BCG at 24 and 72 hrs of cell culture.ResultsAt the end of the experimental time, supernatant was collected to estimate anti-BCG IgG titer, interferon γ, ADA activity, CD 4 and CD8 T cell count, and CD4/CD8 ratio. We demonstrated that PBMC induced with a repeat dose of BCG showed an increased specific anti-mycobacterial immune responses, T cell activity, and ADA activity as compared to PBMC induced with BCG alone or without BCG induction.ConclusionThe repeat BCG stimulation of PBMC obtained from BCG vaccinated individuals shows enhanced immune activation with respect to increased anti-BCG titre, IFN-γ and ADA activity without concomitant increase in CD4 and CD8 cells. This study provides some basic data in future experiments in animal models with respect to repeat BCG vaccination.

Highlights

  • In India, tuberculosis (TB) is the greatest cause of death due to a single pathogen

  • The aim of the present study is to investigate the immune responses to repeated stimulation of peripheral blood mononuclear cells (PBMC)'s from Bacillus Calmette Guérin (BCG) vaccinated healthy volunteers with BCG vaccine

  • Our data indicate that PBMC induced with booster doses of BCG show increased specific anti-mycobacterial immune responses compared to preboost group and control group

Read more

Summary

Introduction

In India, tuberculosis (TB) is the greatest cause of death due to a single pathogen. Bacillus Calmette-Guerin (BCG) is the only vaccine available for clinical use and is one of the most widely used vaccines, being both inexpensive and safe [1,2]. It has been demonstrated that the recombinant BCG vaccine expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induced greater protective immunity against tuberculosis than the conventional BCG vaccine [8]. An interesting complementary approach to improving BCG immunogenicity is its combination in prime-boost immunization protocols [3,5]: priming with a DNA vaccine that expresses antigen 85B and boosting with BCG improves the protective efficacy in a murine M. tuberculosis challenge model [8]. Bacillus Calmette Guérin (BCG) is the only vaccine available for clinical use that protects against miliary TB; this vaccine has shown variable levels of efficacy against pulmonary TB. The incidence of TB in India is very high inspite of primary vaccination in neonatal period and requires consideration for repeated immunization

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call